Abstract
OPMD is a rare (1 in 100,000) hereditary myopathy characterized by progressive ptosis, dysphagia and muscle weakness. NM has the largest cohort of OPMD patients in the US. Majority of OPMD patients develop progressive dysphagia, and cricopharyngeal myotomy had been the main therapeutic modality. Non-surgical approaches including botulinum toxin intramuscular injections (BOTOX) and Upper Esophageal Sphincter (UES) dilation have been reported to be effective in case reports and small clinical series.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
